OS. (A) Entire study population; (B) ibrutinib cohort vs BBB cohort; (C) morphological variant: classic vs blastoid vs pleomorphic variant; and (D) CNS POD >24 months vs ≤24 months. P refers to P values from the log-rank test. Other therapy cohort was not included in (B-D).